In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Global Vision

Set Alert for Global Vision

How Debiopharm’s Licensing Model Bridges The Biotech And Pharma Gap

Sandra von Meier, head of business development and licensing at Debiopharm explains how the company’s distinctive licensing business model is helping bring new drugs to market.

BioPharmaceutical Cancer

Greater Bay Area Device Adoption Can Be A Steppingstone To China Uptake

Medical devices selected for use in the Guangdong-Hong Kong-Macao Greater Bay Area may potentially be fast-tracked for adoption across mainland China, according to a new industry white paper.

China Hong Kong

Japan’s Biotech Ecosystem Could Be Headed For An Upswing

After decades of lackluster start-up innovation despite award-winning science, Japan’s government and big pharma players are taking steps to spur biotech growth. 

Market Intelligence Research & Development

Entering Estonia: To Build Bigger Castles, You Need A Better Sandbox

Estonia is hoping to  create a brighter future by attracting leading startups to its borders, a process that will bring tax revenues, jobs and infrastructure.

Estonia StartUps and SMEs

AMR, UTI, Breathomics And 3D Printing Technology Innovators Profiled At BioWales 2024

Breathomics, UTI diagnosis and advanced wound healing innovations were among the center stage technologies at BioWales in London 2024.

United Kingdom Innovation

Winds Of Change Must Blow Through Welsh Health Care – Digital Chief At BioWales 2024

Wales must be better at adoption, said Mike Emery, the Welsh government’s digital and innovation officer for health and social care, in conversation with In Vivo.

United Kingdom Market Access

China VBP, Localization And Other Strategies - How Far And Which Way?

Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues. 

China Business Strategies

South Korea Sees Pharma Leadership Transition

Leadership succession is proceeding within South Korean pharmaceutical corporations such as Daiichi Sankyo Korea, Astellas Pharma Korea, Kyowa Kirin Korea as well as MSD Korea.

Asia Pacific South Korea

FDA-EMA Advice Pilot For Complex Generics: What Does Industry Have To Say?

The FDA and EMA have shared perspectives on the parallel scientific advice pilot for complex generics. Now industry stakeholders discuss whether transatlantic convergence is possible or merely a good idea on paper.

Regulation Generic Drugs

The Sustainability Stakes Are Rising: ‘We Cannot Recycle Our Way Out Of This’

The journey to Net Zero, described as ‘the defining issue of our time,’ will get harder in the coming decade. Failure to keep up the pressure will result in more long-term health conditions, increasing deaths and higher costs. The UK NHS is a Net Zero exemplar globally, but without a systemic approach, its compliance efforts could stutter.

Sustainability Medical Device

An Ecosystem For Medtech Funding And Innovation Support – BioWales 2024

Creo Medical and Clinithink are among the healthtech innovators who have benefited from funding and advisory support offered by the Development Bank of Wales. All three gave a take on the current funding environment at BioWales in London 2024.

Market Access United Kingdom

A Snapshot of Updates In The APAC Region

US-China tensions, the increasing importance of Singapore as a doorway to the Asia-Pacific region, growing AI innovation in South Korea and a changing clinical trials landscape in Japan are just some of the recent developments in APAC. 

Market Intelligence Asia Pacific

Accessing Venture Debt From The EIB

Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.

Financing Europe

France: A European Leader In Rare Diseases

France has long been a European leader in rare diseases, from its scientific research and academic hospitals, through to patient advocacy and regulatory reforms that have encouraged R&D. Its biotech and pharmaceutical industries are now leading the way, discovering the next generation of therapies for patients that are often overlooked.

Rare Diseases France

Why Protein Misfolding Diseases Have Been Pharma’s Achilles Heel

Protein misfolding diseases, such as Alzheimer’s, are still largely untreatable and incurable. A leading scientist explains why these diseases pose unique R&D challenges and how researchers are beginning to overcome them.

Innovation Neurology

2024 Radar: UK Medtechs Up The Pace On Sustainability And Assess AI Potential

Three UK medtech companies’ views on how their businesses will be influenced by external factors in the coming year.

United Kingdom Medical Device
See All
UsernamePublicRestriction

Register